Dianthus Therapeutics, Inc. Common Stock
DNTHDianthus Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for rare and life-threatening diseases. The company utilizes innovative approaches in protein engineering and drug discovery to create treatments that address unmet medical needs, particularly in the fields of hematology and immunology. Founded with the goal of advancing precision medicine, Dianthus aims to improve patient outcomes through its specialized therapeutics.
Company News
Sanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.
Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibi...
Cormorant Asset Management acquired 950,000 shares of Dianthus Therapeutics for approximately $55 million in Q1 2026, despite the stock already surging 350% over the past year. The clinical-stage biotech company, which develops monoclonal antibody therapies for severe autoimmune diseases, recently achieved positive Phase 3 trial results and maint...
Nanjing Leads Biolabs and partner Dianthus Therapeutics announced that LBL-047, a bifunctional fusion protein targeting plasmacytoid dendritic cells and B cell function, has been selected for clinical development in three autoimmune indications: Sjögren's disease, systemic lupus erythematosus, and dermatomyositis. A Phase 1 study initiated in De...
Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares worth approximately $739,000 on April 9, 2026, through an option exercise and immediate sale under a Rule 10b5-1 plan. The transaction reduced his direct common stock holdings to zero, though he retains 71,776 unexercised stock options. The sale appears to be routine liquidity management rat...
